Page last updated: 2024-12-08
cladribine triphosphate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 452857 |
CHEMBL ID | 4594368 |
CHEBI ID | 172731 |
SCHEMBL ID | 1064481 |
MeSH ID | M0256545 |
Synonyms (18)
Synonym |
---|
[[(2r,3s,5r)-5-(6-amino-2-chloropurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate |
CHEBI:172731 |
2-cldatp |
adenosine 5'-(tetrahydrogen triphosphate), 2-chloro-2'-deoxy- |
106867-30-5 |
2-chloro-2'-deoxyadenosine-5'-triphosphate |
[[(2r,3s,5r)-5-(6-amino-2-chloro-purin-9-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate |
SCHEMBL1064481 |
2-chlorodeoxyadenosine triphosphate |
DTXSID60910156 |
2-chloro-9-[2-deoxy-5-o-(hydroxy{[hydroxy(phosphonooxy)phosphoryl]oxy}phosphoryl)pentofuranosyl]-9h-purin-6-amine |
(((2r,3s,5r)-5-(6-amino-2-chloro-9h-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl)triphosphoric acid |
CHEMBL4594368 |
DCX7XZ96Y2 |
2-chloro-2'-deoxyadenosine 5'-triphosphate |
2-chloro-2'-deoxyadenosine 5'-(tetrahydrogen triphosphate |
cladribine triphosphate |
({[({[(2r,3s,5r)-5-(6-amino-2-chloro-9h-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" Pharmacokinetic and pharmacodynamic interactions between CdA and ara-C during therapy were investigated." | ( Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Chucrallah, A; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W, 1996) | 0.29 |
"The pharmacokinetic parameters of cladribine (CdA) in patient plasma and its intracellular nucleotides CdA 5'-monophosphate (CdAMP) and CdA 5'-triphosphate (CdATP) were delineated in circulating leukemia cells in 17 patients with chronic lymphocytic leukemia, after the last dose intake and up to 72 h thereafter." | ( Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Albertioni, F; Eriksson, S; Juliusson, G; Liliemark, J; Lindemalm, S; Pettersson, B; Reichelova, V, 1998) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
purine deoxyribonucleoside triphosphate | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (50.00) | 18.2507 |
2000's | 3 (30.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (30.00%) | 5.53% |
Reviews | 1 (10.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (60.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |